For pharma customers worldwide, Aptar Pharma, is your go-to drug delivery partner, from formulation to patient, providing innovative drug delivery systems, components and active material solutions across the widest range of delivery routes.
As a global leader in OINDP systems design and technology, pharmaceutical companies turn to Aptar Pharma for proven inhaled drug delivery solutions as well as nasal drug repositioning projects. Aptar Pharma is leading the way in developing sustainable metered-dose inhalers with low GWP propellants, to reduce the environmental impact of inhalers.
Aptar Pharma Services provide a wide array of early-stage to commercialization support to accelerate and derisk the drug development journey, and includes analytical, lab, development and patient onboarding services from industry experts Nanopharm, Gateway Analytical, and Noble.
With a strong focus on innovation, Aptar Digital Health is leading the way in developing digital healthcare solutions to enhance patient experiences.
World-leading formulation expertise, decades of device systems design experience, and a global network of 14 GMP manufacturing sites help us provide security of supply and local support to customers, and deliver end-to-end support for all your drug product development needs. Aptar Pharma is part of AptarGroup, Inc.
Broad Range of OINDP Systems and Integrated Development Services:
Aptar Pharma offers a full range of Orally Inhaled and Nasal Drug Product (OINDP) drug delivery systems and advanced integrated development services for intranasal drug delivery including device systems manufacture, formulation development and nasal cast tests through to clinical and commercial product manufacturing. Aptar Pharma offers a complete range of technologies for the treatment of chronic and acute respiratory conditions.
Our Range of Inhalation Drug Delivery Technologies:
Aptar Pharma’s inhalation drug delivery device technologies supports some of the most successful commercially approved asthma and COPD therapeutics. Our range includes Pressurized Metered Dose Inhalers (pMDIs), Breath Actuated Inhalers (BAIs), Dry Powder Inhalers (DPIs), and innovative solutions like PureHale®, a portable, ready-to-use, fine mist dispensing system that targets delivery to the upper airways.
Aptar Pharma
12-14 Rue Louis Blériot
Rueil-Malmaison 92500
France
+33 (0) 1 39 17 20 20
www.aptar.com/pharma
info.pharma@aptar.com
DPIs
Orbital™: Orbital is Aptar Pharma’s advanced DPI technology, a novel, easy-to-use device that delivers high-payload powder drug formulations directly to the lungs. It is a single-use or reusable, adaptable, hand-held dry powder inhaler that provides many advantages over nebulizer or powder capsule drug delivery methods for a growing range of molecules.
Quattrii: Aptar Pharma collaborates with Cambridge Healthcare Innovations (CHI) to commercialize the Quattrii Dry Powder Inhaler (DPI) technology, which is engineered to uniquely sweep powder into a vortex for tunable and targeted drug delivery to the lungs. Capable of precisely delivering high payloads of drug doses of up to 100mg of dry powder formulation, flexible lung delivery and powder classification, Quattrii marks a new chapter in Aptar Pharma’s expertise in inhaled drug delivery, opening the door to inhaled drug delivery for a number of new indications.
More Info
Nasal Drug Delivery
Aptar Pharma’s Unidose and Bidose nasal spray devices can reliably deliver precise nasal drug dosing in a simple, easy to use, safe, and portable way for both systemic and local administration with rapid onset capabilities. The nasal drug delivery route is Ideal for new drug formulations, drug repositioning and life-cycle management strategies, offering differentiated products with enhanced patient benefits. More Info
Drug Repositioning
Aptar Pharma is a leading global expert in repositioning existing drug products to nasal spray or nasal powder formulations in our proprietary nasal delivery systems. Nasal drug repositioning is a convenient and non invasive drug delivery route that has several medical and business advantages such as life cycle management opportunities, speed to market, ease of use and patient convenience and compliance.
Aptar Pharma’s nasal delivery devices meet the requirements of reliability, rapid onset, simplicity of use, portability and convenience that are required for delivering emergency or crisis medications making treatment more accessible in emergency situations outside of a medical setting.
More Info
Aptar Digital Health
Aptar Digital Health, a division of Aptar Pharma, offers a broad range of innovative and industry-leading digital health solutions including companion apps, Software-as-Medical-Devices, connected devices, disease management platforms, and data and study services leveraging a holistic ecosystem of digital interventions.
Our digital health solutions are patient-friendly, easy and intuitive to use, and are available as fully integrated technologies or add-ons.
More InfoAptar Pharma Services
Aptar Pharma offers a range of specialist analytical, laboratory and regulatory services to add value at every stage of the drug development process. These can accelerate and de-risk your drug development program along the way and we offer end-to-end support at every stage of your drug development journey.
Our broad range of services for respiratory drug development are offered by Nanopharm and Noble, both Aptar Pharma companies.
Nanopharm is a world-leading specialist contract research organization (CRO) offering product design and development services for orally inhaled and nasal drug products (OINDPs).
Noble is a global leader in developing patient-centric solutions throughout the product development and commercialization process including HF/UX/ID services, patient training devices, and enhanced patient engagement solutions.
More Info
Metered Dose Valve Platform for Pressurized Metered Dose Inhalers
The DF30 metering valve is a reliable standard for today’s pressurized metered-dose inhalers (pMDIs). Refined over decades, it powers many asthma and COPD medications, delivering medication safely and consistently. Aptar Pharma’s proprietary technology ensures outstanding performance with a wide range of pMDI formulations and is compatible with both traditional hydrofluoralkane (HFA) propellants and newer, lower Global Warming Potential (GWP) propellants (HFA152a and HFO1234ze). Aptar Pharma can meet your sustainable pMDI propellant filling needs. More Info
